About Beijing Leadman Biochemistry Company

The company was founded in November 1997 and successfully listed on the Shenzhen Stock Exchange GEM on February 16, 2012, stock code: 300289. The company is headquartered in the Beijing Economic and Technological Development Zone. It consists of three parts: a production area, an R&D area, and a living service area. The total construction area is 100,000 square meters, and the daily output of biochemical reagents can reach 4,000 liters. Leadman has an R&D center that has reached international advanced standards and the first medical reference laboratory for in vitro diagnostic companies approved by CNAS in Beijing, and has been included by JCTLM in the medical reference measurement service laboratory database. Currently, 18 projects have passed the 2022 RELA. The company is a national high-tech enterprise with core competitiveness in the fields of in vitro diagnostic reagents, diagnostic instruments, biochemical raw materials, etc., integrating R&D, production and sales. The company's products cover diagnostic reagents, diagnostic instruments and biochemical raw materials in the fields of biochemistry, immunity, blood coagulation, etc. In vitro diagnostic reagent products include biochemical, immunological and coagulation diagnostic reagent products; in vitro diagnostic instrument products include fully automatic chemiluminescence immunoassays, fully automatic biochemical analyzers, hemagglutination analyzers, etc.; biochemical raw materials include biological enzymes, coenzymes, antigens, antibodies, fine chemicals, etc. The company's honors include: winning the “2017 China Listed Company's Most Socially Responsible Award” in the 2017 Financial Industry Listed Company Value Award; winning the 2016 Four New Enterprise Innovation Award in Shanghai's Pudong New Area; winning the 2016 “Safety Star” award from the Beijing Economic and Technological Development Zone; and winning the honorary title of “Shuxiang Enterprise” in the Beijing Economic and Technological Development Zone in 2023.